Advertisement

Topics

BRIEF—New company targets immunotherapies for genetically-defined type 1 diabetes and other autoimmune diseases

10:54 EST 10 Nov 2017 | thePharmaLetter

ImmunoMolecular Therapeutics (IM Therapeutics), a company developing personalized small molecule therapies…

Original Article: BRIEF—New company targets immunotherapies for genetically-defined type 1 diabetes and other autoimmune diseases

NEXT ARTICLE

More From BioPortfolio on "BRIEF—New company targets immunotherapies for genetically-defined type 1 diabetes and other autoimmune diseases"

Advertisement
Quick Search
Advertisement
Advertisement